Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Update

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 9,500,000 shares, an increase of 8.1% from the December 15th total of 8,790,000 shares. Approximately 7.6% of the shares of the company are sold short. Based on an average daily volume of 1,670,000 shares, the short-interest ratio is currently 5.7 days.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock traded down $0.57 during midday trading on Friday, reaching $54.80. 942,028 shares of the stock were exchanged, compared to its average volume of 1,331,984. The company’s fifty day moving average is $49.62 and its 200-day moving average is $54.11. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The firm has a market cap of $6.97 billion, a PE ratio of 18.15, a PEG ratio of 0.40 and a beta of 1.24.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. HC Wainwright upped their price target on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Insiders Place Their Bets

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC grew its position in Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares in the last quarter. Skandinaviska Enskilda Banken AB publ purchased a new position in shares of Halozyme Therapeutics during the second quarter worth about $49,000. Toth Financial Advisory Corp bought a new position in shares of Halozyme Therapeutics in the third quarter worth approximately $57,000. FSC Wealth Advisors LLC purchased a new stake in Halozyme Therapeutics in the third quarter valued at approximately $65,000. Finally, Park Place Capital Corp lifted its position in Halozyme Therapeutics by 828.1% during the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 1,209 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.